Harpreet Singh (via Allogeneic Cell Therapies Summit)

TCR play­er Im­mat­ics com­bines with Per­cep­tive’s blank check op­er­a­tor, scoop­ing $252M and gain­ing a list­ing on Nas­daq

Per­cep­tive Ad­vi­sors’ blank check com­pa­ny has inked a deal — and it’s land­ing right in the mid­dle of a glob­al pan­dem­ic that’s roil­ing the in­dus­try.

Their Arya Sci­ences ven­ture, which com­plet­ed an IPO in the fall of 2018, will now com­bine with TCR play­er Im­mat­ics — a biotech with roots in Ger­many and Hous­ton. That gives Im­mat­ics $148 mil­lion sit­ting in Arya’s cof­fers plus $104 mil­lion in added fund­ing from a group of in­vestors led by Per­cep­tive.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.